BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer 2012;130:2845-56. [PMID: 21780108 DOI: 10.1002/ijc.26292] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 10.1] [Reference Citation Analysis]
Number Citing Articles
1 Fornaro L, Vivaldi C, Parnofiello A, Ugolini C, Aprile G, De Maglio G, Pecora I, Iacono D, Crivelli F, Catanese S, Cardellino GG, Lencioni M, Vasile E, Salani F, Clerico M, Calvetti L, Falcone A, Fasola G, Fontanini G, Montagnani F. Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. Br J Cancer 2019;120:522-6. [PMID: 30745584 DOI: 10.1038/s41416-019-0399-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araújo A, de Mello RA. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J Gastroenterol. 2013;19:6383-6397. [PMID: 24151357 DOI: 10.3748/wjg.v19.i38.6383] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
3 Wang XY, Zheng ZX, Sun Y, Bai YH, Shi YF, Zhou LX, Yao YF, Wu AW, Cao DF. Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. World J Gastrointest Oncol 2019;11:335-47. [PMID: 31040898 DOI: 10.4251/wjgo.v11.i4.335] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
4 Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol. 2016;22:1139-1159. [PMID: 26811653 DOI: 10.3748/wjg.v22.i3.1139] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
5 Bar-Sela G, Hershkovitz D, Haim N, Kaidar-Person O, Shulman K, Ben-Izhak O. The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. Oncol Lett 2013;5:559-63. [PMID: 23420289 DOI: 10.3892/ol.2012.1031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
6 Fang W, Cui H, Yu D, Chen Y, Wang J, Yu G. Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis. Med Oncol 2014;31:15. [PMID: 24924473 DOI: 10.1007/s12032-014-0015-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
7 Gu J, Zheng L, Zhang L, Chen S, Zhu M, Li X, Wang Y. TFF3 and HER2 expression and their correlation with survival in gastric cancer. Tumour Biol 2015;36:3001-7. [PMID: 25514872 DOI: 10.1007/s13277-014-2933-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
8 Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, Di Gregorio C, Scardoni M, Amato E, Frizziero M, Sperduti I, Corbo V, Brunelli M, Bersani S, Tortora G, Scarpa A. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol. 2013;24:693-701. [PMID: 23131390 DOI: 10.1093/annonc/mds506] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
9 Nie S, Yang G, Lu H. Current Molecular Targeted Agents for Advanced Gastric Cancer. Onco Targets Ther. 2020;13:4075-4088. [PMID: 32494161 DOI: 10.2147/ott.s246412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
10 Alvarado-Cabrero I, Gil-Hernández S, Ruelas-Perea A, Villaverde-Rodríguez D, Montes-Ochoa JR, Medrano-Guzmán R. [Immunohistochemical assessment of HER2 expression in gastric cancer. A clinicopathologic study of 93 cases]. Cir Cir 2017;85:504-9. [PMID: 28069112 DOI: 10.1016/j.circir.2016.11.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Berezowska S, Novotny A, Bauer K, Feuchtinger A, Slotta-Huspenina J, Becker K, Langer R, Walch A. Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas. PLoS One. 2013;8:e69098. [PMID: 23874879 DOI: 10.1371/journal.pone.0069098] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
12 Gu J, Zheng L, Wang Y, Zhu M, Wang Q, Li X. Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. Tumour Biol. 2014;35:5315-5321. [PMID: 24557541 DOI: 10.1007/s13277-014-1693-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
13 Chung HW, Lim JB. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol. 2014;20:1667-1680. [PMID: 24587646 DOI: 10.3748/wjg.v20.i7.1667] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
14 Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ, Oh DY. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. Gastric Cancer 2016;19:421-30. [PMID: 26002144 DOI: 10.1007/s10120-015-0504-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
15 Inokuchi M, Murase H, Otsuki S, Kawano T, Kojima K. Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer. World J Surg Oncol. 2017;15:2. [PMID: 28056982 DOI: 10.1186/s12957-016-1081-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
16 Dai X, Zhang X, Yu J. Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer. Clin Exp Gastroenterol 2019;12:287-94. [PMID: 31303779 DOI: 10.2147/CEG.S212895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecol Oncol 2020;159:17-22. [PMID: 32709539 DOI: 10.1016/j.ygyno.2020.07.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
18 Laboissiere RS, Buzelin MA, Balabram D, De Brot M, Nunes CB, Rocha RM, Cabral MM, Gobbi H. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterol 2015;15:157. [PMID: 26530403 DOI: 10.1186/s12876-015-0384-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Limon D, Gal O, Gordon N, Katz L, Perl G, Purim O, Amit L, Stemmer SM, Kundel Y, Ben-Aharon I, Brenner B, Siegal T, Yust-Katz S. Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. J Neurooncol 2018;138:315-20. [PMID: 29429124 DOI: 10.1007/s11060-018-2798-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Baiocchi GL, Molfino S, Baronchelli C, Giacopuzzi S, Marrelli D, Morgagni P, Bencivenga M, Saragoni L, Vindigni C, Portolani N, Botticini M, De Manzoni G. Recurrence in node-negative advanced gastric cancer: Novel findings from an in-depth pathological analysis of prognostic factors from a multicentric series. World J Gastroenterol 2017;23:8000-7. [PMID: 29259375 DOI: 10.3748/wjg.v23.i45.8000] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Fang Z, Tian Z, Luo K, Song H, Yi J. Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients. Chin J Cancer Res. 2014;26:602-610. [PMID: 25400427 DOI: 10.3978/j.issn.1000-9604.2014.10.08] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
22 Katai H, Ishida M, Yamashita H, Ohashi M, Morita S, Katayama H, Fukagawa T, Kushima R. HER2 Expression in Carcinomas of the True Cardia (Siewert Type II Esophagogastric Junction Carcinoma). World J Surg 2014;38:426-30. [DOI: 10.1007/s00268-013-2256-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
23 Merrett ND. Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects. World J Gastroenterol. 2014;20:12892-12899. [PMID: 25278686 DOI: 10.3748/wjg.v20.i36.12892] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
24 Jácome AA, Wohnrath DR, Scapulatempo Neto C, Carneseca EC, Serrano SV, Viana LS, Nunes JS, Martinez EZ, Santos JS. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. Gastric Cancer. 2014;17:76-86. [PMID: 23455716 DOI: 10.1007/s10120-013-0236-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
25 Shi R, Wang L, Wang T, Xu J, Wang F, Xu M. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma. Med Oncol 2014;31:852. [PMID: 24469954 DOI: 10.1007/s12032-014-0852-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
26 Song H, Zhu J, Lu D. Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database Syst Rev 2016;7:CD011461. [PMID: 27432490 DOI: 10.1002/14651858.CD011461.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
27 Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol. 2015;141:1343-1351. [PMID: 25544671 DOI: 10.1007/s00432-014-1900-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
28 Pye H, Butt MA, Reinert HW, Maruani A, Nunes JP, Marklew JS, Qurashi M, Funnell L, May A, Stamati I, Hamoudi R, Baker JR, Smith ME, Caddick S, Deonarain MP, Yahioglu G, Chudasama V, Lovat LB. A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy. Photochem Photobiol Sci 2016;15:1227-38. [PMID: 27501936 DOI: 10.1039/c6pp00139d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
29 Fu X, Zhang Y, Yang J, Qi Y, Ming Y, Sun M, Shang Y, Yang Y, Zhu X, Gao Q. Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer. Onco Targets Ther 2018;11:6091-100. [PMID: 30275713 DOI: 10.2147/OTT.S174138] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
30 Tao R, Li Q, Gao X, Ma L. Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma. Oncol Lett 2018;15:5879-86. [PMID: 29552218 DOI: 10.3892/ol.2018.8030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-khoueiry R. Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014;24:588-596. [PMID: 25203738 DOI: 10.1097/fpc.0000000000000091] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Jia YX, Li TF, Zhang DD, Fan ZM, Fan HJ, Yan J, Chen LJ, Tang H, Qin YR, Li XY. The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study. Onco Targets Ther 2016;9:5919-29. [PMID: 27729801 DOI: 10.2147/OTT.S111778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
33 Araki I, Hosoda K, Yamashita K, Katada N, Sakuramoto S, Moriya H, Mieno H, Ema A, Kikuchi S, Mikami T. Prognostic impact of venous invasion in stage IB node-negative gastric cancer. Gastric Cancer. 2015;18:297-305. [PMID: 24687437 DOI: 10.1007/s10120-014-0362-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
34 Gu MJ, Hong S, Jung SJ; The Korean Small Intestinal Cancer Study Group. HER2 protein expression and HER2 gene amplification are infrequent in small intestinal carcinomas. Virchows Arch 2013;462:603-7. [DOI: 10.1007/s00428-013-1425-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Fan M, Hu W, Zhang Z. Chemoradiation for gastric cancer: controversies, updates and novel techniques. Br J Radiol 2015;88:20150027. [PMID: 25827208 DOI: 10.1259/bjr.20150027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
36 Tang D, Liu CY, Shen D, Fan S, Su X, Ye P, Gavine PR, Yin X. Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. Onco Targets Ther. 2015;8:7-14. [PMID: 25565860 DOI: 10.2147/OTT.S70922] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
37 Liu L, Cao L, Gong B, Yu J. Novel biomarkers for the identification and targeted therapy of gastric cancer. Expert Rev Gastroenterol Hepatol 2015;9:1217-26. [PMID: 26220043 DOI: 10.1586/17474124.2015.1072466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
38 Wu X, Huang S. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer. Bulletin du Cancer 2019;106:946-58. [DOI: 10.1016/j.bulcan.2019.03.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
39 Ku GY, Ilson DH. Emerging tyrosine kinase inhibitors for esophageal cancer. Expert Opin Emerg Drugs. 2013;18:219-230. [PMID: 23725567 DOI: 10.1517/14728214.2013.805203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
40 Ueda M, Hisada H, Temma T, Shimizu Y, Kimura H, Ono M, Nakamoto Y, Togashi K, Saji H. Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression. Mol Imaging Biol 2015;17:102-10. [PMID: 25049073 DOI: 10.1007/s11307-014-0769-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
41 Slotta-Huspenina J, Becker KF, Feith M, Walch A, Langer R. Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus. Cancers (Basel) 2014;6:1382-93. [PMID: 24978439 DOI: 10.3390/cancers6031382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
42 Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58. [PMID: 26022204 DOI: 10.1186/s13045-015-0155-z] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 20.0] [Reference Citation Analysis]
43 Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398:27-40. [PMID: 34102137 DOI: 10.1016/S0140-6736(21)00797-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 17.0] [Reference Citation Analysis]
44 Li Z, Xiao Q, Wang Y, Wang W, Li S, Shan F, Zhou Z, Ji J. A Modified ypTNM Staging System-Development and External Validation of a Nomogram Predicting the Overall Survival of Gastric Cancer Patients Received Neoadjuvant Chemotherapy. Cancer Manag Res 2020;12:2047-55. [PMID: 32256112 DOI: 10.2147/CMAR.S236696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Ku GY, Ilson DH. Emerging mAbs for the treatment of esophagogastric cancer. Expert Opinion on Emerging Drugs 2015;20:63-74. [DOI: 10.1517/14728214.2015.983072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Popa EC, Shah MA. Met, IGF1R, and other new targets in upper GI malignancies. Curr Treat Options Oncol. 2013;14:321-336. [PMID: 23873272 DOI: 10.1007/s11864-013-0245-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Liu X, Zhang N, Shi H. Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget 2017;8:62730-41. [PMID: 28977984 DOI: 10.18632/oncotarget.17528] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
48 Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol. 2011;23:744-755. [PMID: 21963299 DOI: 10.1016/j.ceb.2011.09.003] [Cited by in Crossref: 315] [Cited by in F6Publishing: 281] [Article Influence: 31.5] [Reference Citation Analysis]
49 Liang JW, Zhang JJ, Zhang T, Zheng ZC. Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. Tumour Biol. 2014;35:4849-4858. [PMID: 24449506 DOI: 10.1007/s13277-014-1636-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
50 Blay C, Chiforeanu DC, Boucher E, Cabillic F, Desgrippes R, Leconte B, Perrin C, Manfredi S, Audrain O, Meunier B, Edeline J. Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. Acta Oncol 2015;54:1833-5. [PMID: 25753188 DOI: 10.3109/0284186X.2015.1011757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Kanat O, O'Neil B, Shahda S. Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol 2015;7:401-10. [PMID: 26690491 DOI: 10.4251/wjgo.v7.i12.401] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
52 Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist 2012;17:346-58. [PMID: 22334453 DOI: 10.1634/theoncologist.2011-0311] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
53 Cuyun Carter G, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum H, Chen J. Treatment patterns in patients with advanced gastric cancer in Taiwan: Gastric cancer treatment in Taiwan. Asia-Pac J Clin Oncol 2017;13:185-94. [DOI: 10.1111/ajco.12497] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
54 Shen GS, Zhao JD, Zhao JH, Ma XF, Du F, Kan J, Ji FX, Ma F, Zheng FC, Wang ZY, Xu BH. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China. World J Gastroenterol 2016;22:5406-14. [PMID: 27340357 DOI: 10.3748/wjg.v22.i23.5406] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
55 Nagaraja V, Eslick GD. HER2 expression in gastric and oesophageal cancer: a meta-analytic review. J Gastrointest Oncol 2015;6:143-54. [PMID: 25830034 DOI: 10.3978/j.issn.2078-6891.2014.107] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
56 Junior PN, Neto RA, Forones NM. HER2 EXPRESSION AS A PROGNOSTIC FACTOR IN METASTATIC GASTRIC CANCER. Arq Gastroenterol 2016;53:62-7. [PMID: 27305410 DOI: 10.1590/S0004-28032016000200003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013;8:76. [PMID: 23656792 DOI: 10.1186/1746-1596-8-76] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
58 Personeni N, Baretti M, Bozzarelli S, Spaggiari P, Rubino L, Tronconi MC, Fumagalli Romario U, Rosati R, Giordano L, Roncalli M, Santoro A, Rimassa L. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer 2017;20:428-37. [PMID: 27530622 DOI: 10.1007/s10120-016-0625-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
59 Ding N, Sano K, Kanazaki K, Ohashi M, Deguchi J, Kanada Y, Ono M, Saji H. In Vivo HER2-Targeted Magnetic Resonance Tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody. Mol Imaging Biol 2016;18:870-6. [PMID: 27351762 DOI: 10.1007/s11307-016-0977-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
60 Vaidyanathan K, Vasudevan DM. Organ Specific Tumor Markers: What's New? Indian J Clin Biochem 2012;27:110-20. [PMID: 23542399 DOI: 10.1007/s12291-011-0173-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
61 Roy PS, Nyodu T, Hazarika M, Saikia BJ, Bhuyan C, Inamdar A, Nyuthe CW, Borthakur B, Sharma JD. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population. Asian Pac J Cancer Prev 2019;20:1139-45. [PMID: 31030487 DOI: 10.31557/APJCP.2019.20.4.1139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Gutiérrez-González A, Belda-Iniesta C, Bargiela-Iparraguirre J, Dominguez G, García Alfonso P, Perona R, Sanchez-Perez I. Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair. Apoptosis 2013;18:347-60. [PMID: 23271172 DOI: 10.1007/s10495-012-0794-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
63 Tian X, Zhu Q, Zhang Z. Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review. Onco Targets Ther 2021;14:3701-8. [PMID: 34135598 DOI: 10.2147/OTT.S305039] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Morishita A, Gong J, Masaki T. Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol. 2014;20:4536-4545. [PMID: 24782606 DOI: 10.3748/wjg.v20.i16.4536] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
65 Yao Y, Liu Z, Guo H, Huang S, Zhong M, Deng J, Xiong J. Elevated TRIM23 expression predicts poor prognosis in Chinese gastric cancer. Pathol Res Pract 2018;214:2062-8. [PMID: 30477642 DOI: 10.1016/j.prp.2018.10.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
66 Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012;18:546-54. [PMID: 22252257 DOI: 10.1158/1078-0432.CCR-11-2272] [Cited by in Crossref: 98] [Cited by in F6Publishing: 43] [Article Influence: 10.9] [Reference Citation Analysis]
67 Lv Q, Meng Z, Yu Y, Jiang F, Guan D, Liang C, Zhou J, Lu A, Zhang G. Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer. Int J Mol Sci 2016;17:E2095. [PMID: 27983617 DOI: 10.3390/ijms17122095] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
68 Liu X, Xu P, Qiu H, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer. Onco Targets Ther 2016;9:949-58. [PMID: 27013889 DOI: 10.2147/OTT.S100979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
69 Ansari S, Gantuya B, Tuan VP, Yamaoka Y. Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity. Int J Mol Sci 2018;19:E2424. [PMID: 30115886 DOI: 10.3390/ijms19082424] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 8.7] [Reference Citation Analysis]
70 Vizeacoumar FS, Guo H, Dwernychuk L, Zaidi A, Freywald A, Wu FX, Vizeacoumar FJ, Ahmed S. Mining the plasma-proteome associated genes in patients with gastro-esophageal cancers for biomarker discovery. Sci Rep 2021;11:7590. [PMID: 33828156 DOI: 10.1038/s41598-021-87037-w] [Reference Citation Analysis]
71 He XX, Ding L, Lin Y, Shu M, Wen JM, Xue L. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. J Clin Pathol 2015;68:374-80. [PMID: 25731189 DOI: 10.1136/jclinpath-2014-202657] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
72 Azhdarinia A, Ghosh P, Ghosh S, Wilganowski N, Sevick-Muraca EM. Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis. Mol Imaging Biol 2012;14:261-76. [PMID: 22160875 DOI: 10.1007/s11307-011-0528-9] [Cited by in Crossref: 80] [Cited by in F6Publishing: 61] [Article Influence: 8.9] [Reference Citation Analysis]
73 Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Bull Cancer 2015;102:324-31. [PMID: 25744576 DOI: 10.1016/j.bulcan.2014.08.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
74 Warneke VS, Behrens HM, Böger C, Becker T, Lordick F, Ebert MP, Röcken C. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 2013;24:725-33. [PMID: 23139264 DOI: 10.1093/annonc/mds528] [Cited by in Crossref: 87] [Cited by in F6Publishing: 71] [Article Influence: 9.7] [Reference Citation Analysis]
75 Behrens HM, Warneke VS, Böger C, Garbrecht N, Jüttner E, Klapper W, Mathiak M, Oschlies I, Rudolph U, Stuhlmann-Laeisz C. Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule. Cancer Med. 2015;4:235-244. [PMID: 25515030 DOI: 10.1002/cam4.365] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
76 Xiao SM, Xu R, Tang XL, Ding Z, Li JM, Zhou X. Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report. Oncol Lett 2018;16:2085-90. [PMID: 30008904 DOI: 10.3892/ol.2018.8942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
77 Topletz-Erickson AR, Lee AJ, Mayor JG, Rustia EL, Abdulrasool LI, Wise AL, Dailey B, DeChenne S, Walker LN, Alley SC, Endres CJ. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. J Clin Pharmacol 2021;61:461-71. [PMID: 32989831 DOI: 10.1002/jcph.1750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
78 Zhang SS, Wu LH, Liu Q, Chen KS, Zhang XF. Elevated expression of NEDD9 is associated with metastatic activity in gastric cancer. Onco Targets Ther 2015;8:633-40. [PMID: 25792847 DOI: 10.2147/OTT.S77904] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
79 Namikawa T, Maeda M, Yokota K, Tanioka N, Fukudome I, Iwabu J, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Assessment of Systemic Inflammatory Response and Nutritional Markers in Patients With Trastuzumab-treated Unresectable Advanced Gastric Cancer. In Vivo 2020;34:2851-7. [PMID: 32871824 DOI: 10.21873/invivo.12112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma. Int J Cancer 2016;139:1626-31. [PMID: 27198655 DOI: 10.1002/ijc.30200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
81 Lv J, Yao YS, Zhou F, Zhuang LK, Yao RY, Liang J, Qiu WS, Yue L. Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma. Med Oncol 2014;31:280. [PMID: 25297519 DOI: 10.1007/s12032-014-0280-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
82 Koopman T, Louwen M, Hage M, Smits MM, Imholz AL. Pathologic Diagnostics of HER2 Positivity in Gastroesophageal Adenocarcinoma. American Journal of Clinical Pathology 2015;143:257-64. [DOI: 10.1309/ajcpcx69hgddgycq] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects. World J Gastroenterol. 2014;20:4526-4535. [PMID: 24782605 DOI: 10.3748/wjg.v20.i16.4526] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
84 Yamashita-kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate. Cancer Chemother Pharmacol 2019;83:659-71. [DOI: 10.1007/s00280-019-03768-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
85 Huang LT, Ma JT, Zhang SL, Li XH, Sun L, Jing W, Zhao JZ, Wang YR, Han CB. Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report. Front Oncol 2019;9:1453. [PMID: 31956604 DOI: 10.3389/fonc.2019.01453] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
86 Fan XS, Chen JY, Li CF, Zhang YF, Meng FQ, Wu HY, Feng AN, Huang Q. Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol 2013;19:3316-23. [PMID: 23745034 DOI: 10.3748/wjg.v19.i21.3316] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
87 Röcken C. [Ways to personalized medicine for gastric cancer]. Pathologe 2013;34:403-12. [PMID: 23907566 DOI: 10.1007/s00292-013-1785-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
88 Lordick F, Röcken C. The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer. Annals of Oncology 2013;24:1135-8. [DOI: 10.1093/annonc/mdt111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
89 Hu J, Yin B. Advances in biomarkers of biliary tract cancers. Biomed Pharmacother 2016;81:128-35. [PMID: 27261586 DOI: 10.1016/j.biopha.2016.02.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
90 Patil PS, Mehta SA, Mohandas KM. Over-expression of HER2 in Indian patients with gastric cancer. Indian J Gastroenterol 2013;32:350. [PMID: 23111642 DOI: 10.1007/s12664-012-0279-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
91 Damasceno EA, Carneiro FP, Magalhães AV, Carneiro Mde V, Takano GH, Vianna LM, Seidler HB, Castro TM, Muniz-Junqueira MI, Amorim RF, Ferreira VM, Motoyama AB. IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status. J Cancer Res Clin Oncol 2014;140:2163-8. [PMID: 25323937 DOI: 10.1007/s00432-014-1850-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
92 Baniak N, Senger JL, Ahmed S, Kanthan SC, Kanthan R. Gastric biomarkers: a global review. World J Surg Oncol. 2016;14:212. [PMID: 27514667 DOI: 10.1186/s12957-016-0969-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]